Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07220060 and PF-07104091 in Advanced Solid Tumors and Breast Cancer
NCT05262400Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of atirmociclib and tegtociclib in breast cancer and solid tumor (11 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities at 28 days, Treatment emergent adverse events at 2 years and 3 more. Started Mar 2022; status: active, not recruiting.
02
Drugs
atirmociclibtegtociclib
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT05262400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262400.